Franklin Street Advisors Inc Biocryst Pharmaceuticals Inc Transaction History

Franklin Street Advisors Inc

$1.48 Billion
Q3 2024

A detailed history of Franklin Street Advisors Inc transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Franklin Street Advisors Inc holds 60,000 shares of BCRX stock, worth $436,200. This represents 0.03% of its overall portfolio holdings.

Number of Shares

60,000

Previous 60,000 -0.0%

Holding current value

$436,200

Previous $371,000 22.91%

% of portfolio

0.03%

Previous 0.03%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 10, 2023	BUY	$6.71 - $7.92 $67,100 - $79,200	10,000 Added 20.0%	60,000 $425,000
Q2 2021 Aug 05, 2021	BUY	$9.5 - $17.24 $475,000 - $861,999	50,000 New	50,000 $791,000
Q1 2021 May 04, 2021	SELL	$7.37 - $13.61 $589,600 - $1.09 Million	-80,000 Closed	0 $0
Q4 2020 Feb 01, 2021	BUY	$3.37 - $8.61 $16,850 - $43,050	5,000 Added 6.67%	80,000 $596,000
Q1 2020 Apr 16, 2020	BUY	$1.6 - $4.11 $40,000 - $102,750	25,000 Added 50.0%	75,000 $150,000
Q4 2019 Feb 14, 2020	SELL	$1.59 - $3.45 $22,260 - $48,300	-14,000 Reduced 21.88%	50,000 $173,000
Q3 2019 Nov 14, 2019	BUY	$2.5 - $3.73 $125,000 - $186,500	50,000 Added 357.14%	64,000 $183,000
Q2 2019 Aug 07, 2019	SELL	$2.91 - $9.15 $145,500 - $457,500	-50,000 Reduced 78.13%	14,000 $53,000
Q1 2019 May 14, 2019	BUY	$7.38 - $9.72 $147,600 - $194,400	20,000 Added 45.45%	64,000 $521,000
Q4 2018 Feb 14, 2019	BUY	$6.51 - $9.6 $6,510 - $9,600	1,000 Added 2.33%	44,000 $355,000
Q2 2018 Jul 16, 2018	SELL	$4.6 - $6.52 $27,599 - $39,120	-6,000 Reduced 12.24%	43,000 $246,000
Q3 2017 Oct 11, 2017	BUY	$4.1 - $5.97 $200,899 - $292,530	49,000	49,000 $257,000

Others Institutions Holding BCRX

# of Institutions

280

Shares Held

172M

Call Options Held

625K

Put Options Held

739K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.35B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Franklin Street Advisors Inc , based on Form 13F filings with the SEC.

News

Stay updated on Franklin Street Advisors Inc with notifications on news.

Account

Franklin Street Advisors Inc Biocryst Pharmaceuticals Inc Transaction History